The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Amgen's cholesterol drug Repatha has been given the green light in Europe, making it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

and efficacy of AMG145 on LDL-C in subjects with severe familial hypercholesterolemia Clinical Phase II study Amgen AMG145 is a human monoclonal IgG2 that binds specifically to PCSK9 The ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...